A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19

Completed

Conditions studied: SARS-CoV-2 Acute Respiratory Disease

In brief

The primary objective of this study is to describe the longevity of IgG against SARS-CoV-2 infection or vaccination.

Key facts

Study ID

NCT05042193

Run by

Everly Health

People needed

1883

Starts

2021-03-19

Expected to finish

2022-06-14

Last updated by the study team

2022-06-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age ≥ 18 years
• Willing to provide informed consent prior to participation.
• Cohort 1 (Arm 1) - Positive test results for SARS-CoV-2 virus by an RT-PCR or Antigen test AND not received any COVID-19 vaccine or participated in any COVID-19 vaccine trial
• Cohort 2 (Arm 2) - Received the COVID-19 vaccine

You may not qualify if…

• Unable or unwilling to provide informed consent
• Individuals with known conditions or treatments associated with immune impairment, such as cancer and chemotherapy

Where it is running

• Everlywell, Inc — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.